Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus abiraterone/prednisone versus abiraterone/prednisone in metastatic castration-resistant prostate cancer
NL-OMON60659Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in prostate cancer (PCa) and castration-resistant prostate cancer (CRPC) comparing Abemaciclib + abiraterone acetate + prednisone with Abiraterone acetate + prednisone (2 arms). Primary endpoints: Radiographic Progression Free Survival and Recommended Phase 2 Dose. Started Jan 2019; status: completed.
02
Drugs
abemaciclibabirateroneprednisone
03
Conditions
prostate cancer (PCa)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON60659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60659.